Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial

NCT03042312 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.

NCT NCT03042312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
Lead sponsor
Endocyte
Phase
Phase 2
Overall status
Terminated
Start date
July 12, 2017
Completion date
January 15, 2020
Enrollment
71 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer